Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Recruiting 9Unknown 3Active not recruiting 3Withdrawn 1Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell 3Neoplasm, Residual 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Leukemia, Lymphocytic, Chronic, B-Cell 2Burkitt Lymphoma 2Stomach Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Mesothelioma, Malignant 1Meningeal Carcinomatosis 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Lymphoid 1Leukemia 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Rituximab 16Cyclophosphamide 16Prednisone 7Doxorubicin 7pirtobrutinib 6fludarabine 6Vincristine 6Lenalidomide 6venetoclax 5pembrolizumab 5fludarabine phosphate 5Etoposide 5Bendamustine Hydrochloride 5ibrutinib 4acalabrutinib 4Specimen Handling 4Magnetic Resonance Spectroscopy 4Dexamethasone 4CT-P10 4polatuzumab vedotin 3etoposide phosphate 3Immunotherapy, Adoptive 3tazemetostat 2liposomal doxorubicin 2Nivolumab 2Injections 2Ifosfamide 2Gemcitabine 2Cisplatin 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, B-Cell × Immunotherapy, Adoptive × Clear all
NCT03277729 2026-01-05

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Fred Hutchinson Cancer Center

Phase 1/2 Active not recruiting
53 enrolled 11 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06464185 2025-11-18

A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma

Institute of Hematology & Blood Diseases Hospital, China

Phase 1/2 Active not recruiting
48 enrolled
Lymphoid

Lymphoma, B-Cell

NCT07094477 2025-07-30

Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell Lymphoma

Chinese PLA General Hospital

Phase 2 Active not recruiting
50 enrolled
Lymphoid

Lymphoma, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡